

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ascletis Pharma Inc.

歌禮製藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1672)

VOLUNTARY ANNOUNCEMENT

ASCLETIS ANNOUNCES ORAL AND POSTER PRESENTATIONS ON ASC47, AN ADIPOSE-TARGETED, MUSCLE-PRESERVING WEIGHT LOSS DRUG CANDIDATE FOR OBESITY AT THE 32ND EUROPEAN CONGRESS ON OBESITY

This announcement is made by Ascletis Pharma Inc. (the “**Company**” or “**Ascletis**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On Obesity (ECO 2025) in Malaga, Spain.

Oral Presentation Details

Title: ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice

Abstract Category/Topic: Obesity Management and Intervention » Emerging treatments

Abstract Number: 0254

Session: T1 Abstract Session: Novel Drugs. The Seeds for the Future Are Here

Session Date and Time: 11:30-13:00, 13 May 2025 (Malaga Time), 17:30-19:00, 13 May 2025 (Beijing Time)

Presenter: Jinzi Jason Wu

Poster (Guided Poster) Presentation Details

Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study

Abstract Number: 0816

Abstract Category/Topic: Obesity Management and Intervention » Emerging treatments

Session: Track Specific Poster Networking Session

Session Date and Time: 18:00-19:10, 13 May 2025 (Malaga Time), 00:00-01:10, 14 May 2025 (Beijing Time)

Presenter: Jinzi Jason Wu

About ASC47

ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THR β) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) ([NCT06427590](#)) have been released. The U.S. Investigational New Drug (IND) application for ASC47 in combination with semaglutide for the treatment of obesity has been cleared by U.S. Food and Drug Administration (FDA).

About European Congress on Obesity

Established in 1986, European Association for the Study of Obesity (EASO) is a federation of professional membership associations from 38 European countries. European Congress on Obesity (ECO) is EASO's annual scientific congress. The ECO brings together colleagues from every area of obesity research, prevention and management.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize ASC47 successfully.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People's Republic of China
May 6, 2025

As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.